The panel comprised SMs in 23 genes: TERT (promoter), FGFR3,PIK3CA,TP53,ERCC2,RHOB,ERBB2,HRAS,RXRA,ELF3,CDKN1A,KRAS,KDM6A,AKT1,FBXW7,ERBB3,SF3B1,CTNNB1,BRAF, C3orf70,CREBBP,CDKN2A, and NRAS; 93.5–98.3% of UBCs of all grades and stages harboured ≥1 SM (mean: 2.5 SMs/tumour). This evidence concerns the gene KRAS and neoplasm.